{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-004162","form_type":"8-K","ticker":"CYPH","cik":"0001509745","company_name":"CYPHERPUNK TECHNOLOGIES INC.","filed_at":"2024-01-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.425132+00:00","generated_at":"2026-06-06T23:07:56.119185+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Leap Therapeutics reports 30% ORR and 93% DCR in Part A of DeFianCe study for DKN-01 in second-line CRC","bullets":["Across 27 evaluable microsatellite stable CRC patients: ORR 30%, DCR 93%, median PFS 6.3 months.","Left-sided tumors: 33% ORR, 100% DCR, preliminary median PFS 8.6 months.","Rectal/rectosigmoid subgroup (n=15): 46% ORR, 100% DCR, preliminary median PFS 9.4 months.","DKN-01 plus bevacizumab and chemotherapy well-tolerated; majority of related events Grade 1/2.","Part B of study enrolling well, expected to complete enrollment mid-2024; conference call January 23."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-004162","json":"https://secwatch.observer/filing/0001104659-24-004162.json","markdown":"https://secwatch.observer/filing/0001104659-24-004162.md","text":"https://secwatch.observer/filing/0001104659-24-004162.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924004162/0001104659-24-004162-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1509745/000110465924004162/tm243430d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T23:07:56.119185+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}